Lymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab Induction
Alemtuzumab, an anti-CD52 T-cell and B-cell depleting monoclonal antibody, is established for induction therapy in renal transplantation (KTx). We herein provide a comparative analysis between alemtuzumab and basiliximab induction therapy and correlate lymphocyte depletion and recovery with the clin...
Saved in:
Main Authors: | Annemarie Weissenbacher, Theresa Hautz, Michael Kimelman, Rupert Oberhuber, Hanno Ulmer, Claudia Bösmüller, Manuel Maglione, Stefan Schneeberger |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2015/985460 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of alemtuzumab-mediated lymphocyte depletion on SIV reservoir establishment and persistence.
by: Benjamin Varco-Merth, et al.
Published: (2024-08-01) -
The immunological bases of alemtuzumab as induction-therapy in pediatric-onset multiple sclerosis
by: Marco Puthenparampil, et al.
Published: (2025-01-01) -
Our Unique Experience with Low-Dose Alemtuzumab as an Induction Agent for Renal Transplantation: A Case Series
by: Cherin Josi, et al.
Published: (2024-12-01) -
Basiliximab is superior to low dose rabbit anti-thymocyte globulin in pediatric kidney transplant recipients: The younger, the better
by: Lan Zhu, et al.
Published: (2025-01-01) -
Induction of Oxidative Stress in Kidney
by: Emin Ozbek
Published: (2012-01-01)